NPHC.US Nutra Pharma Corp

Healthcare Biotechnology USA Stocks
0.0002 USD
Close of Nov 12, 2026
Market cap
USD 1.43M
P/E
-
P/B
46.56x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is NPHC.US undervalued?

Graham number

The Graham number of Nutra Pharma Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nutra Pharma Corp fundamental analysis

No fundamental analysis for Nutra Pharma Corp yet.

Nutra Pharma Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nutra Pharma Corp

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin/Nyloxin Extra Strength, an over-the-counter (OTC) pain reliever; Pet Pain-Away, a homeopathic, non"narcotic, non"addictive, over"the"counter pain reliever to treat moderate to severe chronic …

Full company profile